- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03213808
VALIDATION OF THE CHAPTER "ALLERGIES AND HYPERSENSITIVITY" OF THE INTERNATIONAL DISEASE CLASSIFICATION (CIM) (AHCIM11)
ANALYSIS OF HEALTH DATA COLLECTED SYSTEMATICALLY BY THREE HOSPITALS FOR THE VALIDATION OF THE CHAPTER "ALLERGY AND HYPERSENSITIVITY" IN THE FUTURE VERSION 11 OF THE WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL CLASSIFICATION OF DISEASES (CIM)
Allergic diseases, including allergic asthma, allergic rhinitis and anaphylaxis are not properly classified in current classifications of diseases. We here propose a project based on the evaluation of medical records of hospital databases of patients suffering for allergic and hypersensitivity conditions coded with the current and a new coming version of the international classification of diseases, no patient or intervention will be analysed.
We here propose a study to update and reach quality assurance of the classification of allergic and hypersensitivity conditions in international classification systems. The Allergic and hypersensitivity conditions section has indeed been recently built into the new ICD-11 framework and we aim to reach its quality assurance by evaluating medical records of French hospital databases. All the consecutive cases related to allergic and hypersensitivity conditions registered in the last 1 year will be selected and blind-coded by two independent coders based on the online English versions of the ICD-10 (2015 version) and ICD-11 Beta draft. The generated data will support the intra and inter-variability testing, survey among end-users and economic-impact evaluation. The economic impact of the transition from ICD-10 to ICD-11 will be analysed based on average estimated cost per day of each principal diagnosis and the effect of the classification change will be quantified by the cost variance of inter or intra diagnosis of ICD-10 and ICD-11. For the bridge procedure based on the alignment of the allergic and hypersensitivity conditions described into the ICD-10 (and ICD-10 CM US adaptation) framework to the ICD-11 beta phase, we propose the mapping and cross-linking terms methods. Meanwhile, we will start updating the allergic and hypersensitivity procedures by influencing the International Classification of Health Intervention (ICHI).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale for this Non-Interventional Study Allergic diseases, including allergic asthma, allergic rhinitis and anaphylaxis are not properly classified in current classifications of diseases. We here propose a project based on the evaluation of medical records of hospital databases of patients suffering for allergic and hypersensitivity conditions coded with the current and a new coming version of the international classification of diseases, no patient or intervention will be analized.
Objectives of this Non-Interventional Study Main Objectives: To assess the stability of codes for ICD-10 allergic diseases and hypersensitivity to ICD-11 using the medical-administrative databases of 3 hospitals.
Secondary Objectives: (I) To adjust the terms and links for allergic diseases and hypersensitivity and thus continue the on-line implementation process of ICD-11 based on the lessons learned on the main objective; (II) To estimate the economic impact of ICD-10 and ICD-11 transition for health care facilities; (III) To electronically align ICD-10 codes (and CM adaptation in the USA) with ICD-11.
Study design All the consecutive cases of allergies over a year and registered in the DIM bases of 3 healthcare establishments (the university hospital of Montpellier (CHRUM), Paris (APHP), Toulouse) will be individualized. Depending on the size of the facility, ½ to 1/10 of the cases will be included in the study. All cases will be selected anonymously. Two professional coders will encode the selected cases twice. The analysis of the data will be based on the degree of inter-encoder agreement using Cohen's Kappa coefficient. At the end of this process, we will be able to identify the correspondence between the codes recorded in the DIM database (ICD-10) and those of the new classification. In the event of discordant results, consensus will be reached by involving other coding experts from CHRUM. The economic impact of the transition from ICD-10 to ICD-11 will be approximated by estimating the average costs per ICD code used in the main diagnosis.
Target subject population Our project is focused on allergic and hypersensitivity sufferers. Although we intend to validate the classification of allergic and hypersensitivity conditions, the international classification systems are for global use and our methodology might be helpful for other diseases and for the program of medicalization and information system (PMSI).
Statistical methods In order to reach the inter and intra-variability testing, the data analysis will be based on the degree of inter-rater agreement using Cohen's Kappa.
The economic impact of the transition from ICD-10 to ICD-11 will be analized based on average estimated cost per day of each principal diagnosis and the effect of the classification change will be quantified by the cost variance of inter or intra diagnosis of ICD-10 and ICD-11.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Pascal DEMLY, MD, PhD
- Phone Number: 33 467336118
- Email: p-demoly@inserm.fr
Study Locations
-
-
-
Montpellier, France, 34295
- Recruiting
- Uhmontpellier
-
Contact:
- PASCAL DEMOLY, MD, phD
- Phone Number: 33 467336118
- Email: p-demoly@inserm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion criteria:
- We here propose a study based on hospital database medical records. The cases will be selected based on pre-established (ICD-10) allergy corresponding codes: respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis).
The prescription of the medicinal product is clearly separated from the decision to include the subject in the non-interventional study
Exclusion criteria:
- We will exclude from the study all cases in which the ICD-10 codes are not related to allergic and hypersensitivity conditions.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
respiratory allergies
respiratory allergies (asthma, rhinitis)
|
No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
|
skin allergies
skin allergies (dermatitis, urticarial, angioedema)
|
No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
|
anaphylaxis
|
No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
|
gastrointestinal allergic conditions
|
No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
|
ocular allergies
ocular allergies (conjunctivitis)
|
No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intra and inter-variability measures among coders and accuracy rate calculation
Time Frame: 1 day
|
Ease of use, level of ambiguity on a 0-4 scale
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Classification of Diseases -10, -10CM and -11 term alignement
Time Frame: 1 day
|
International Classification of Diseases -10, -10CM and -11 term alignement
|
1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insertion of allergy procedures in the International Classification of Health Interventions (ICHI)
Time Frame: 1 day
|
Insertion of allergy procedures in the International Classification of Health Interventions (ICHI)
|
1 day
|
Health economics related the transition from the ICD-10 to ICD-11: cost variance of inter or intra diagnosis of ICD-10 and ICD-11
Time Frame: 1 day
|
Health economics related the transition from the ICD-10 to ICD-11: cost variance of inter or intra diagnosis of ICD-10 and ICD-11
|
1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF9863
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ALLERGIC OR HYPERSENSITIVITY
-
Cytos Biotechnology AGCompletedPerennial Allergy to House Dust Mite and/or CatEstonia, Latvia, Lithuania
-
General Administration of Military Health, TunisiaRecruitingStudy the Efficacy of ITA in Patients With Allergic Asthma or Allergic Rhinitis or Allergic Rhinitis Compared With Conventional TreatmentTunisia
-
Rush University Medical CenterGlaxoSmithKlineCompletedAllergic Conjunctivitis to Tree Pollen or Grass PollenUnited States
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedSeasonal Allergic ConjunctivitisChina
-
NovartisAlcon ResearchCompletedSeasonal Allergic ConjunctivitisChina
-
Rush University Medical CenterRecruitingContact Allergic Dermatitis | Adverse Skin ReactionUnited States
-
Laboratoires TheaCompletedSeasonal Allergic ConjunctivitisFrance
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisSingapore
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisUnited States
-
Eleven BiotherapeuticsCompletedAllergic Conjunctivitis (AC)United States
Clinical Trials on No intervention: analysis of health data from patients with
-
Xijing HospitalRecruiting
-
Nantes University HospitalRecruitingSevere Trauma (With or Without Traumatic Brain Injury)France
-
Nantes University HospitalCompletedSevere Brain InjuryFrance
-
Nantes University HospitalWithdrawn
-
University Hospital, Basel, SwitzerlandCompletedFracture-associated Infection (FAI)Switzerland
-
University Hospital, Basel, SwitzerlandCompletedPituitary AdenomaMalaysia, Switzerland
-
University Hospital, MontpellierNeurogenetic department, CHU Bordeaux; Genetic Department , CHU Montpellier-France and other collaboratorsUnknown
-
University of Erlangen-Nürnberg Medical SchoolCompletedOAC-ICH | Acute Management of OAC-ICH | Resumption of OAC
-
Sophiahemmet UniversitySwedish Diabetes Foundation; OneTwo Analytics AB; SophiahemmetRecruiting
-
University Hospital, MotolCompletedRefractory Respiratory FailureCzechia